Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Ablaze Pharmaceuticals logo — Leading the Innovative Targeted Radiotherapy Landscape in Ch...

Ablaze Pharmaceuticals

Leading the Innovative Targeted Radiotherapy Landscape in China.

Founded 2021 China Shanghai, China 10 employees Series A Total: $75.00M Biotechnology, Pharmaceutical

General Information

Company Name Ablaze Pharmaceuticals
Founded Year 2021
Location China Shanghai, China
Employees 10
Industries Biotechnology, Pharmaceutical
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Ablaze Pharmaceuticals . To contact Ablaze Pharmaceuticals , visit ablazepharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Ablaze Pharmaceuticals compare?

A PDF of Ablaze Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Ablaze Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Ablaze Pharmaceuticals

Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company founded in 2011 with a mission to revolutionize the targeted radiotherapy landscape in China. The company has garnered attention for its partnership with RayzeBio, Inc., a leading radiopharmaceutical firm based in San Diego, CA. This strategic alliance has granted Ablaze exclusive rights for development and commercialization of a range of RayzeBio’s products in the greater China region. With a focus on the burgeoning market for targeted radiopharmaceutical therapies (TRT), Ablaze is poised to emerge as a pioneering force in this sector in China by collaborating with key partners both domestically and internationally. The latest milestone for Ablaze Pharmaceuticals was the $75.00M Series A investment on 29 November 2021, with a consortium of prominent investors including Vivo Capital, AdvanTech Capital, Nan Fung Life Sciences, Samsara BioCapital, VenBio Partners, Pivotal bioVenture Partners China, Venrock Healthcare Capital Partners, and RAYZ Investments. Ablaze Pharmaceuticals' commitment to advancing innovative radiopharmaceutical therapies in China positions it as a compelling prospect for investment in the biotechnology and pharmaceutical industries. For more information, please visit www.ablazepharma.com.

Business keywords: Pharmaceuticals, Clinical-stage, Radiopharmaceuticals, Cancer treatment, Targeted therapy, Drug development, Partnership, Radiopharmaceutical company, Cross-border product development, Business networking, China market, Strategic partnerships, Healthcare innovation, Oncology

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $75.00M 8
Vivo Capital AdvanTech Capital Nan Fung Life Sciences
Vivo Capital, AdvanTech Capital +6
29 Nov 2021

Ablaze Pharmaceuticals Alternatives & Competitors

View All Alternatives
Ablaze Pharmaceuticals vs
ARIZ Precision Medicine
ARIZ Precision Medicine United States

Targeting Cancer at the Root Cause

Seed
2 employees
Biotechnology, Health Care
Ablaze Pharmaceuticals vs
RayzeBio
RayzeBio United States

Targeted innovative radiopharmaceuticals for cancer

Acquired
258 employees
Biotechnology, Health Care
Compare Ablaze Pharmaceuticals vs RayzeBio
Ablaze Pharmaceuticals vs
Rexahn Pharmaceuticals
Rexahn Pharmaceuticals United States

TARGETING DIFFICULT TO TREAT CANCERS

Post-IPO Equity
7 employees
Biotechnology, Medical Devices
View all alternatives

FAQ About Ablaze Pharmaceuticals

Leading the Innovative Targeted Radiotherapy Landscape in China.
Ablaze Pharmaceuticals was founded in 2021.
Ablaze Pharmaceuticals is headquartered in Shanghai, China.
Ablaze Pharmaceuticals operates in Biotechnology and Pharmaceutical. Its work centres on Pharmaceuticals, Clinical-stage, Radiopharmaceuticals and Cancer treatment.
Ablaze Pharmaceuticals has approximately 10 employees.
Ablaze Pharmaceuticals has completed 1 funding round, raising a total of $75.00M. The latest funding stage is Series A.
Top alternatives and competitors to Ablaze Pharmaceuticals include ARIZ Precision Medicine, RayzeBio, Rexahn Pharmaceuticals, Aktis Oncology, Santaris Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ablaze Pharmaceuticals and ARIZ Precision Medicine are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ablaze Pharmaceuticals , https://bouncewatch.com/company/ablaze-pharmaceuticals, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes